The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster vaccine and strokes in people aged 65 or over, but still recommend the ...

Dr. Tedros Adhanom Ghebreyesus declares the end of the COVID-19 pandemic, highlighting global vaccination efforts and future pandemic preparedness.

Pfizer currently is the only company with ... ABRYSVO is an unadjuvanted, bivalent vaccine that was designed to provide broad protection against RSV-LRTD, regardless of the virus subgroup.

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74 Pfizer Inc ... is an unadjuvanted, bivalent vaccine that was designed to ...

Here’s what that means If the FDA panel’s recommendation is endorsed by the CDC, only a single composition of vaccine – in this case, the updated bivalent ... Pfizer's says its COVID-19 ...

The panel typically does not vote on its influenza or COVID-19 vaccine ... monovalent Arexvy (GSK), Pfizer’s bivalent Abrysvo, and Moderna’s monovalent mRNA vaccine, mResvia, for adults ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

ABRYSVO is an unadjuvanted, bivalent vaccine that ... the impact of COVID-19 on our business, operations and financial results; and competitive developments. A further description of risks and ...